Ann: Quarterly Activities Report and Appendix 4C, page-5

Hi Sidage,

Sales invoicing: that's not what I understood - for tax they have to count the sale as the date of the invoice on the order. On what grounds do you believe that reported invoiced sales may not actually eventuate (outside of normal bad debts which companies can expect due to non-payment, which is normally very small)?

Clarity of sales: Agreed, but they have issued MediCabilis numbers. They have previously stated that the sales to H&H are a mix of CBII products and the Swisse range of 9 products. Competition would no doubt be keen to know the precise units, so I'm not surprised that they want to keep those close to their chest!

With the groundwork done and sales starting to come in, cash burn has reduced, so even if it were to stay at the current rate, they have more than a year (using last quarter cash + R&D refund). H&H relationship gives me confidence that, if they even did need cash, they have support in high places!

No news in this compared to the update, other than the Dir payment, which is a small amount.
Can't be many with profits to take at the moment!
DYOR - I did mine